• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

2.825 -0.145 (-4.88%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,691
Open 2.930
Bid (Size) 2.800 (4,900)
Ask (Size) 2.880 (4,200)
Prev. Close 2.970
Today's Range 2.754 - 3.060
52wk Range 2.754 - 54.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
November 10, 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years ↗
November 05, 2026
The drugmaker hasn't disappointed long-term shareholders. 
Via The Motley Fool
Topics Intellectual Property

Performance

52-Week Range 94.9% below 52-week high
2.825
2.7552W Low 54.9752W High
1 Week 15.8% below 1-week high
2.751W Low 3.361W High

Sionna Therapeutics, Inc. - Common Stock (SION) traded between $2.75 and $54.97 over the past 52 weeks and last traded at $2.83, 94.9% below its 52-week high. Over the past week it ranged between $2.75 and $3.36.

Past 12 Months
-9.5%
-27.0%
-46.6%
-93.1%
-92.8%
-92.7%
1W -$0.29
1M -$1.04
3M -$2.46
6M -$38.30
YTD -$36.38
1Y -$36.11

SION was -92.7% over the past year, -93.1% over six months, -92.8% year to date, -9.5% in the last week.

12 Months vs Market
SION
-92.7%
DIA
+5.0%
SPY
+4.1%
QQQ
+1.4%
IWM
+12.0%

Over the past 12 months SION returned -92.7% versus DIA (Dow) +5.0%, SPY (S&P 500) +4.1%, QQQ (Nasdaq 100) +1.4% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.48× 3-mo avg
Today 550,691 3-mo avg 1.1M
1W
563.0K
1M
794.8K
3M
1.1M
6M
1.4M
YTD
956.1K
1Y
885.2K

SION most recently traded 550,691 shares against a 3-month average daily volume of 1.1M.

More News

Read More
News headline image
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
November 02, 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
October 08, 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗
September 18, 2026
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
September 14, 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
September 04, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
September 02, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
September 01, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
August 25, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
August 20, 2026
Via The Motley Fool
News headline image
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
August 19, 2026
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
August 18, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
August 18, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
August 17, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
August 17, 2026
From Robbins LLP
Via Business Wire
News headline image
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
August 16, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
August 14, 2026
Via The Motley Fool
News headline image
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
August 14, 2026
From Levi & Korsinsky, LLP
Via Business Wire
These stocks have an unusual volume in today's session ↗
August 13, 2026
Via Chartmill

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 2.825
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 11/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap